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Abstract
Background: It is yet to be established which factors are responsible for differences among
patients with the same degree of coronary artery disease in terms of coronary collateral develo-
pment (CCD).
Methods: Patients who had a greater than or equal to 95% stenosis in at least one epicardial
coronary artery were classified into two groups according to their glomerular filtration rate (GFR)
level. Afterwards, the degree of CCD was evaluated according to their plasma concentration of
asymmetric dimethylarginine (ADMA) and GFR levels.
Results: Rentrop grade 2–3 was found more frequently in patients with GFR > 60 mL/min
than in patients with GFR < 60 mL/min (68.6% vs 41.4%, p = 0.032). Then we divided
patients into four groups according to their GFR levels and Rentrop grades; whereas we did
not find any significant difference for L-arginine or ADMA levels (respectively p = 0.629 and
p = 0.076), we did find a statistically significant difference between groups for L-arginine/
/ADMA ratio (p = 0.003) and this statistically significant difference was evident between
patients with GFR < 60 mL/min and Rentrop 0–1 and patients with GFR > 60 mL/min and
Rentrop 2–3 (1.23 vs 1.69, p < 0.001). Multivariate logistic regression analysis revealed that
L-arginine/ADMA ratio was the only variable which had a significant effect on CCD (OR = 1.016;
95% CI 1.001–1.031, Wald = 4.565; p = 0.033).
Conclusions: These results showed that CCD was poor in patients with GFR < 60 mL/min,
presumably because of the adverse effect of decreased L-arginine/ADMA ratio on endothelial
cells and angiogenesis. (Cardiol J 2012; 19, 1: 29–35)
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Introduction
The prognosis and severity of coronary artery
disease (CAD) is not uniform among patients with
similar traditional risk factors. Therefore, condi-
tions other than traditional cardiovascular (CV) risk
factors should always be kept in mind.
One of these is the presence of coronary col-
lateral development (CCD). Sufficient collateral
network limits infarct size, preserves myocardial
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function and improves the prognosis. Thus, patients
become less symptomatic despite the presence of
chronic total coronary occlusion. A negative corre-
lation has been shown in studies examining the ef-
fect of CV risk factors on CCD [1, 2]. It is still un-
certain why there are differences among patients
in terms of developing coronary collaterals and
which factors can affect this process.
Endothelium plays a crucial role in the main-
tenance of vascular structure, control of vascular
tonus, homeostasis, and inflammation. Also, endo-
thelium plays a pivotal role in all steps of collateral
development. Asymmetric dimethylarginine
(ADMA) is an endogenous inhibitor of nitric oxide
synthesis (NOS) and competes with L-arginine for
the active site of endothelial NOS. ADMA decreas-
es the production and bioavailability of nitric oxide
(NO), and thus decreases the vessel compliance,
increases vascular resistance and limits the blood
flow [3].
CCD may be influenced by plasma ADMA le-
vel and endothelial dysfunction resulting from im-
paired NOS. Although there are animal studies in-
vestigating the relationship between CCD and plas-
ma ADMA level in the literature, few clinical studies
have examined this relationship in humans and in
patients with chronic kidney disease. CCD can be
influenced by the existence of multiple potential
anti-angiogenic factors and impaired angiogenesis
in patients with chronic kidney disease.
In the current study, we aimed to investigate
the relationship between glomerular filtration rate
(GFR) and plasma ADMA level and CCD.
Methods
Study population
Between June 2008 and July 2009, patients in
whom coronary angiography (CAG) was performed
due to a high clinical suspicion of CAD, and a great-
er than or equal to 95% stenosis in at least one epi-
cardial coronary artery, were enrolled in this study.
Refusal to participate, acute myocardial infarction
(AMI) in the past month, clinically unstable coro-
nary syndrome, type 1 diabetes mellitus, uncon-
trolled hypertension (sysctolic blood pressure
> 190 mm Hg), previous coronary artery bypass graft
(CABG) operation, severe systemic inflammatory
disease and hepatic failure were regarded as exclu-
sion criteria. Seventy eight patients in all were as-
sessed, of whom 17 were excluded due to the exclu-
sion criteria (two patients because of acute myocar-
dial infarction in the past month, two patients
because of CABG surgery and 13 patients because
of the absence of significant CAD at CAG). The re-
maining 61 patients constituted the study population.
Glomerular filtration rate
Patients were classified into two groups ac-
cording to their estimated GFR values using the six
variable modifications of diet in renal disease
(MDRD) equation. Group 1 consisted of 29 patients
with CAD and estimated GFR < 60 mL/min/1.73 m2
and Group 2 consisted of 32 patients with CAD and
estimated GFR > 60 mL/min/1.73 m2.
Coronary angiography
Standard selective CAG with at least four views
of the left coronary system and two views of the
right coronary artery using the Judkins technique
were performed. Coronary artery stenosis greater
than or equal to 95% in at least one epicardial coro-
nary artery was determined as the lesion which
could make possible the development of a coronary
collateral. CCD was graded according to the Rent-
rop classification [4]. Rentrop grade (RG) 0–1 was
regarded as poor CCD, and RG 2–3 was regarded
as good CCD.
Measurement of plasma ADMA level
Before CAG, venous blood samples for ADMA
measurement were collected into tubes which in-
cluded EDTA as an anticoagulant. The collected
blood samples were centrifuged for 10 min at
200 rpm to separate the plasma. All plasma sam-
ples were stored frozen at –80oC before use. Plas-
ma concentrations of ADMA and L-arginine were
measured by high-performance liquid chromoto-
graphy (HPLC) using the technique of Chen et al.
[5]. An Agilent 1100 series HPLC device and fluo-
rescence detector and 150 × 4.6 mm THERMO
Hypersil ODS 5 µm analytic column were used.
Total analysis time was 40 min.
All the patients enrolled in the study gave writ-
ten informed consent. This study was carried out in
accordance with the Declaration of Helsinki and ap-
proved by the local Ethics Committee of our Institute.
Statistical analysis
Data gained from patients was transferred to
the computer. The error control and corrections
were done. Data was tested graphically and statis-
tically for normal distribution using Shapiro-Wilk
analysis. All results for continuous variables with
normal distribution were expressed as mean ±
± standard deviation (SD) and skewed variables as
median (interquartile range — IQR). Categorical
variables were defined as percentages. Differences
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between categorical variables (e.g. group, sex, hy-
pertension, diabetes) were analyzed using c2 test
and c2 likelihood ratio. Students’ t test was used to
compare the continous variables with normal dis-
tribution, and Mann-Whitney U test was used for
skewed variables between two groups. Spearman’s
and Pearson’s correlation coefficients were used for
correlation analysis. A linear regression analysis
model was used to explain the parameters which
may effect the plasma ADMA level. Backward step-
wise multivariate logistic regression model was per-
formed to determine the effect of independent risk
factors for coronary collateral development. A p £
£ 0.05 was considered statistically significant.
MS-Excel and SPSS 15.0 Statistical Package Pro-
gram for Windows (SPSS Inc., Chicago, IL, USA)
were used for all statistical analysis and calculations.
Results
A total of 61 patients (15 women and 46 men)
aged 41–88 years (mean age 69.31 ± 7.01 years)
were enrolled in this study. The mean age of pa-
tients was 70.86 ± 9.41 years in Group 1 and 67.90 ±
± 3.31 years in Group 2 (p = 0.101). There was no
statistically signficant difference for basal demo-
graphic and clinical features between the two
groups, except gender (p = 0.021). Whereas there
was no diagnosis of CKD in Group 2, 11 (37.9%) of
29 patients had CKD in Group 1 (p < 0.001). The
mean estimated GFR value was 37.32 ± 16.35 mL/
/min for Group 1 and 83.67 ± 16.37 mL/min for
Group 2 (p < 0.001). LDL-cholesterol levels were
higher in Group 1 than in Group 2 (respectively,
124.00 ± 41.35 mg/dL vs 103.96 ± 35.93 mg/dL,
p = 0.047; Table 1).
The severity of CAD was similar between the
two groups. There was no statistically significant dif-
ference in the number of disease vessels, number of
total occluded vessels or type of occluded vessel be-
tween the two groups (p > 0.05 for all; Table 2). The
relationship between GFR levels and RG was evalu-
ated by c2 test. A good coronary collateral develop-
ment (RG 2–3) was present in 41.4% of patients with
GFR < 60 mL/min/1.73 m2 and in 68.8% of patients
with GFR > 60 mL/min/1.73 m2 (p = 0.032).
Table 1. Basal demographic and clinical features.
Group 1  (n = 29) Group 2  (n = 32) P
N (%)/mean ± SD/median (IQR)
Age (years) 70.86±9.41 67.90±3.31 0.101
Male/female 18/11; 62.1%/37.9% 28/4; 87.5%/12.5% 0.021
Heart rate [bpm] 76.82±16.27 74.46±12.71 0.529
Systolic blood pressure [mm Hg] 131.96±24.39 124.28±20.16 0.184
Diastolic blood pressure [mm Hg] 70.65±13.35 71.25±12.82 0.860
Stable angina pectoris 22 (75.9%) 26 (81.3%) 0.608
Risk factors:
Hypertension 21 (72.4%) 20 (62.5%) 0.414
Diabetes mellitus 9 (31%) 12 (37.5%) 0.596
Hyperlipidemia 5 (17.2%) 11 (34.4%) 0.129
Smoking 10 (34.5%) 18 (56.3%) 0.088
Previous CAD history 19 (65.5%) 21 (65.6%) 0.993
Family history 12 (41.4%) 15 (46.9%) 0.666
Chronic kidney disease 11 (37.9%) 0 (0%) 0.001
Laboratory findings:
Fast blood glucose [mg/dL] 97 (40%) 104.50 (33.8%) 0.222
Total cholesterol [mg/dL] 198.24±52.21 178.46±40.41 0.102
LDL-cholesterol [mg/dL] 124.00±41.35 103.96±35.92 0.047
HDL-cholesterol [mg/dL] 38 (14%) 41 (14.5%) 0.478
Triglycerides [mg/dL] 128.00 (136.5%) 156.00 (107.8%) 0.729
Glomerular filtration rate [mL/min] 37.32±16.35 83.66±16.37 < 0.001
Ejection fraction (%) 45 (16.3%) 54 (18%) 0.125
CAD — coronary artery disease; IQR — interquartile range; SD — standard deviation
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There was no statistically significant difference
between patients with GFR < 60 mL/min/1.73 m2
and patients with GFR > 60 mL/min/1.73 m2 with
regard to L-arginine levels. However, the difference
was statistically significant for plasma ADMA
levels and L-arginine/ADMA ratio (respectively,
p = 0.043 and p = 0.008; Table 3). Higher plasma
ADMA level and lower L-arginine/ADMA ratio were
found in patients with GFR < 60 mL/min/1.73 m2 than
those of GFR > 60 mL/min/1.73 m2.
In linear regression analysis, GFR and the
number of diseased vessels were found to be fac-
tors responsible for the increase of plasma ADMA
level (respectively, beta = –0.336; p = 0.010 and
beta = 1.182; p < 0.001). When all patients enrolled
in the study were evaluated together, we found
a significant negative correlation between plasma
ADMA level and GFR level (r = –0.405, p = 0.001).
We compared the L-arginine level, ADMA level
and L-arginine/ADMA ratio between the good co-
ronary collateral group (RG 2–3) and the poor col-
lateral group (RG 0–1). Whereas there was no sta-
tistically significant difference in plasma L-arginine
or ADMA level, a statistically significant difference
for L-arginine/ADMA ratio was found (p = 0.001;
Table 4).
After we categorized the patients according to
their GFRs and RGs into four groups, we evaluat-
ed L-arginine (with One-Way ANOVA test) level,
plasma ADMA level and L-arginine/ADMA ratio
(with Kruskal Wallis test) between the groups. We
did not find a significant difference for L-arginine
or ADMA concentration (respectively, p = 0.629
and p = 0.076). However, we found a statistically
significant difference for L-arginine/ADMA ratio
(p = 0.003) between groups, and this statistically
significant difference was prominent between pa-
tients with GFR < 60 mL/min/1.73 m2 and RG 0–1
and patients with GFR > 60 mL/min/1.73 m2 and
RG 2–3 (1.23 vs 1.69, p < 0.001; Table 5).
Table 4. Relationship between Rentrop grades and plasma asymmetric dimethylarginine (ADMA) levels.
RG 0–1 (n =27) RG 2–3 (n = 34) P
Mean ± SD/median (IQR)
L-arginine [mmol/L] 16.56 ± 7.03 18.54 ± 7.33 0.291
ADMA [mmol/L] 13.01 (11.9) 12.01 (9.9) 0.089
L-arginine/ADMA ratio 1.23 (0.7) 1.68 (0.8) 0.001
RG — Rentrop grade; IQR — interquartile range; SD — standard deviation
Table 2. Coronary angiography findings.
Group 1 (n = 29) Group 2 (n = 32) P
Number of diseased vessels — median (IQR) 3.00 (IQR = 0.00) 3.00 (IQR = 0.00) 0.051
Number of total occluded vessels 0 3 (10.3%) 1 (3.1%)
1 12 (41.4%) 21 (65.6%) 0.132
2 14 (48.3%) 10 (31.3%)
IQR — interquartile range
Table 3. Relationship between glomerular filtration rate and plasma asymmetric dimethylarginine
(ADMA) levels.
Group 1 (n = 29) Group 2 (n = 32) P
Mean ± SD/median (IQR)
L-arginine [mmol/L] 17.74 ± 6.96 17.59 ± 7.54 0.935
ADMA [mmol/L] 14.97 (11.1) 10.03 (9.8) 0.043
L-arginine/ADMA ratio 1.23 (0.7) 1.64 (0.9) 0.008
IQR — interquartile range; SD — standard deviation
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Backward stepwise multivariate logistic re-
gression analysis including GFR, diabetes mellitus,
hypertension, LDL-cholesterol, smoking, fasting
blood glucose, ADMA and L-arginine/ADMA ratio
was performed in order to elucidate the CCD, and
revealed that L-arginine/ADMA ratio (OR = 1.016,
95% CI 1.001–1.031) was the only independent va-
riable which had a significant effect on CCD (Wald =
= 4.565; p = 0.033).
Discussion
In this study, we found that CCD was better in
patients with GFR > 60 mL/min/1.73 m2 and occlu-
sive CAD compared to those with GFR < 60 mL/
/min/1.73 m2 and occlusive CAD. L-arginine/ADMA
ratio might have an effect on CCD in those patients.
CCD has a pivotal role in the continuation of
myocardial viability. Coronary collateral vessels
protect the myocardium by limiting the border of
myocardial ischemia in case of coronary occlusion,
and symptoms of CAD appear less in the presence
of sufficient coronary blood flow [6]. Pressure gra-
dient and growth factors play an important role in
CCD [7]. At the same time, there is a discrepancy
among patiens with occlusive CAD in view of CCD,
and this suggests that a lot of other factors may have
an effect on CCD.
Studies looking at the effect of CV risk factor
on CCD have shown that CV risk factors associat-
ed with endothelial dysfunction such as diabetes
mellitus, hypertension, and hyperlipdemia had an
adverse effect on CCD [1, 8–10]. There was no sta-
tistically significant difference with regard to these
risk factors between the two groups in our study.
Also, there was no statistically signficant difference
in terms of frequency or duration of stabile angina
pectoris, which has an effect on the development
of coronary collateral [11], between the two groups
in our study (p = 0.608).
Angiogenic adaptation (formation of new ves-
sels) and arteriogenic adaptation (maturation of
these new vessels) are pivotal steps towards CCD.
The stimulation of angiogenesis starts as a physio-
logic response to ischemia and hypoxia, and blood
flow increases to ischemic tissue [12]. Endothelial
cells are an important influence on the development
and maturation of collateral vessels [7].
The results of recent experimental studies
have shown that NO plays a critical role in the main-
tenance of normal endothelial function, angiogene-
sis and arteriogenesis [13]. NO deficiency and en-
dothelial dysfunction due to the existence of multi-
ple potential anti-angiogenic factors in patients with
renal failure has been found to impair the microvas-
cular adaptation and ischemic tolerance of tisssues
[9]. Few studies have examined the effect of low
GFR on CCD. In this study, we pointed out that
CCD was impaired by a decrease in GFR. The poor
CCD in patients with renal failure can be explained
by this impaired ischemic tolerance.
Plasma ADMA level is increased in patients
with CAD compared to healthy subjects, and this
increase predicts all-cause and CV mortality [14].
In CARDIAC study, plasma ADMA concentration
was found to be 20% higher in those with CV dise-
ase, and was increased significantly by several tra-
ditional risk factors [15]. ADMA is mainly eliminat-
ed by renal excretion and begins to accumulate
when renal excretion is impaired. Despite the 2- to
3-fold elevation of ADMA plasma concentration in
many diseases, plasma concentrations of ADMA are
~ten-fold higher in patients with end stage renal
disease. The accumulation of ADMA inhibits NO
production. Increased plasma ADMA level (thus
a decrease of NO) is associated with oxidative stress
and endothelial dysfunction, and impairs CCD in
patients with renal failure [16–18].
In literature, a few studies have revealed that
there is a relationship between plasma ADMA level
and CCD, and CCD is poor in those with increased
plasma ADMA level. Similarly, a very few studies
have indicated the relationship between impaired
renal function and CCD. Our study is the first to
investigate the effect of plasma ADMA concentra-
tion measured according to GFRs on CCD.
Table 5. L-arginine and ADMA levels of patients according to their GFR levels and Rentrop grades.
  L-arginine [µmol/L] ADMA [µmol/L] L-arginine/ADMA ratio
Mean ± SD  Median (IQR)  Median (IQR)
GFR < 60 mL/min/1.73 m2, RG 0–1 16.28 ± 6.04 13.01 (11.0) 1.23 (0.7)
GFR > 60 mL/min/1.73 m2, RG 0–1 17.03 ± 8.81 14.83 (19.1) 1.20 (1.0)
GFR < 60 mL/min/1.73 m2, RG 2–3 19.81 ± 7.88 16.04 (11.5) 1.30 (1.0)
GFR > 60 mL/min/1.73 m2, RG 2–3 17.84 ± 7.10 8.55 (8.1) 1.69 (0.7)
ADMA — asymmetric dimethylarginine; GFR — glomerular filtration rate; RG — Rentrop grade; IQR — interquartile range; SD — standard deviation
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ADMA competes with L-arginine for NOS
and L-arginine level is measured rarely. However,
the L-arginine/ADMA ratio is more important for
NOS function than ADMA alone. When we exami-
ned the L-arginine/ADMA ratio of the patients en-
rolled in our study, we observed that the L-argini-
ne/ADMA ratio was higher in patients with GFR
> 60 mL/min/1.73 m2 and good CCD than in patients
with GFR < 60 mL/min/1.73 m2 and poor CCD
(p < 0.001). Furthermore, L-arginine/ADMA ratio
was found to be the only independent variable which
had a significant effect on CCD in multivariate lo-
gistic regression analysis (p = 0.033).
Therapeutic strategies for increasing L-argini-
ne/ADMA ratio may improve CCD. The pharma-
cological arrangement of plasma ADMA concentra-
tion is an interesting area. The effect of severeal
pharmacological agents on ADMA metabolism has
been investigated in order to increase CCD, also
called ‘natural bypass’, especially in patients with
diffuse and severe CAD who are not good candi-
dates for revascularization (angioplasty or CABG)
[19–25]. Theoretically, arginine should be able to
displace ADMA and restore NOS activity. Exoge-
nous ADMA competes with ADMA, blocks the inhi-
bition of NO production through ADMA, and also acts
as an antioxidant and eliminates the superoxide [16].
Arginine has been reported to improve endothelial
function [26] and increase walking distance [27].
Plasma arginine concentration can be increased [28]
or decreased [29] by pharmacotherapy.
Limitations of the study
This study has a number of limitations. The
small number of patients is the major limitation, and
might disallow the determination of risk factors af-
fecting coronary collateral development. The oth-
er limitation of this study is the evaluation of CCD
by CAG. As is well-known, angiography only visu-
alizes collateral flow in vessels greater than 100 mm
in diameter, and vessels smaller than 100 mm can-
not be detected [30]. This might cause an underes-
timation of the degree of CCD and there might be
a collateral vessel in patients considered to have no
CCD at CAG. Also, only plasma concentrations of
ADMA were measured, and data about the cellular
concentration of ADMA, which might be more as-
sociated with NOS function, is inadequate.
Conclusions
Our findings suggest that the L-arginine/
/ADMA ratio seems to be a more important determi-
nant of NOS function than ADMA alone. Presuma-
bly because of the adverse effect of decreased
L-arginine/ADMA ratio (relatively increased plas-
ma ADMA level) on endothelial cells and angiogene-
sis, CCD is worse in patients with GFR < 60 mL/
/min/1.73 m2 than in those with GFR < 60 mL/min/
/1.73 m2.
Hence, L-arginine/ADMA ratio may be a no-
vel risk marker for predicting CCD in patients with
GFR < 60 mL/min/1.73 m2. Therapeutic strategies
to increase arginine concentrations or decrease
ADMA concentrations may positively influence the
endothelium and angiogenesis by improving NOS
function, and may contribute to CCD (also called
‘biological bypass’), especially in patients not con-
sidered to be good candidates for revascularization.
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